LigoCyte Pharmaceuticals, Inc., is a biotechnology company that uses proprietary technologies to develop a pipeline of therapeutic drugs and vaccines. LigoCyte's unique core technology platforms and intellectual property support the discovery and development of a new generation of immunomodulatory compounds that offer substantial benefits to the patient while minimizing the side effects associated with current immunosuppressive drugs. LigoCyte's vaccine platforms produce strong immune responses at mucosal surfaces, the point of entry for most pathogenic organisms. By applying cell targeting technologies, LigoCyte's vaccines can also be delivered orally or nasally for unprecedented ease of administration.